



Rejoyn

The first FDA-cleared prescription digital therapeutic (PDT) for the adjunctive treatment of Major Depressive Disorder (MDD) symptoms.

<https://www.otsuka-us.com>

Overview

Rejoyn is a prescription digital therapeutic (PDT) developed by Otsuka and Click Therapeutics, and commercialized by Otsuka Precision Health, Inc. It is the first and only FDA-cleared PDT for the treatment of Major Depressive Disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients (age 22 and older) who are on antidepressant medication.

The program is delivered via a smartphone app and consists of a six-week treatment schedule. It is designed to enhance cognitive control of emotion by leveraging the brain's natural ability to change, known as neuroplasticity.

Key Features and Capabilities:

Cognitive Emotional Training (CET): The core of the treatment involves clinically-validated brain-training exercises, such as the Emotional Faces Memory Task (EFMT), designed to target neural networks affected by depression.

Skills-Based Therapy Lessons: The app includes short, animated, skills-based therapy lessons (some CBT-based) to complement the brain exercises.

Adjunctive Treatment: It is intended to be used alongside existing antidepressant medication and does not replace standard care.

Digital Delivery: The program is accessed via a mobile app on iOS and Android devices, requiring a prescription and a digital access code.

Duration: The active treatment program lasts for six weeks, with continued access to completed lessons for an additional four weeks.

Rejoyn is classified as a Class II medical device and was cleared by the FDA in March 2024. Clinical trials showed that adding Rejoyn to antidepressant medication reduced depression symptoms with zero treatment-related adverse events.

Key Features

- FDA-cleared Prescription Digital Therapeutic (PDT)
- 6-week Cognitive Emotional Training (CET) program
- Leverages neuroplasticity to reduce MDD symptoms
- Adjunctive treatment to antidepressant medication
- Skills-based therapy lessons
- Personalized reminders and progress tracking

Pricing

Model: subscription

Prescription required. Available for a limited-time cash-pay price of \$50 for the full 6-week program (full cash price is \$200). The price for payers is \$200. It is reimbursable by HSA/FSA.

Starting at: USD \$50

Target Company Size: enterprise

Compliance & Certifications

FDA 510(k) Clearance, Class II Medical Device

This document was generated by IntuitionLabs.ai with the assistance of AI. While we strive for accuracy, please verify critical information independently.